# Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants

> **NCT02420496** · PHASE2 · WITHDRAWN · sponsor: **The University of Texas Health Science Center at San Antonio**

## Conditions studied

- Cholestasis
- Liver Disease

## Interventions

- **DRUG:** Enteral fish oil
- **DRUG:** Ursodeoxycholic Acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02420496
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420496, "Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02420496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*